Navamedic ASA: Invitation to 2021 Third quarter presentation

Publisert: 28.10.2021

Navamedic ASA extends exclusive distribution rights for Mysimba in the Nordics

Publisert: 12.10.2021

Navamedic ASA receives approval for conditional reimbursement for Mysimba® in Finland

Publisert: 07.09.2021

Navamedic ASA: Q2 and first half 2021 financial results

Publisert: 13.08.2021

Navamedic ASA: Invitation to 2021 Second quarter presentation

Publisert: 10.08.2021

Obesity patient support program launched in Norway

Publisert: 20.05.2021